Cajanolactone A, a stilbenoid from cajanus cajan, prevents ovariectomy-induced obesity and liver steatosis in mice fed a regular diet

• Published in: Phytomedicine (Stuttgart) Vol. 78; p. 153290
• Main Authors: Luo, Zhuo-Hui, Liu, Zhi-Wen, Mao, Yu, Shu, Rong, Fu, Lin-Chun, Yang, Rui-Yi, Hu, Ying-Jie, Shen, Xiao-Ling
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01.11.2020
• Subjects: Adipose Tissue, White - drug effects; Adipose Tissue, White - metabolism; Animals; Anti-Obesity Agents - pharmacology; Apolipoprotein B-100 - genetics; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics; Body Weight - drug effects; Cajanolactone A; Cajanus - chemistry; Cajanus cajan; Diet; Fatty liver; Female; Gene Expression Regulation - drug effects; Lipogenesis - drug effects; Lipogenesis - genetics; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - prevention & control; Obesity - etiology; Obesity - prevention & control; Ovariectomy; Ovariectomy - adverse effects; Postmenopausal obesity; Postmenopause; Proteomics of perigonadal white adipose tissue; Stilbenes - pharmacology; Stilbenes - therapeutic use; Triglycerides - metabolism; Pcx; Aldh2; LDL-C; Ndufa3; PPI; Cajanus cajan; ALT; PRM; WAT; Acly; HDL-C; Fatty liver; KEGG; FSH; AST; Ovariectomy; MS; TCA cycle; GO; Pdhb; Atp5fld; pWAT; Aacs; TC; EV; Echs1; TG; Cajanolactone A; Proteomics of perigonadal white adipose tissue; CLA; TMT; Postmenopausal obesity; Acaca
• ISSN: 0944-7113; 1618-095X
• DOI: 10.1016/j.phymed.2020.153290

Visceral obesity and fatty liver are prevalent in postmenopausal women. The stilbene-rich extract of Cajanus cajan (L.) Millsp. has been reported to prevent ovariectomy-induced and diet-induced weight gain in animal models, and stilbenoids from C. cajan are thought to have the potential to prevent postmenopausal obesity and fatty liver. Cajanolactone A (CLA) is the main stilbenoid from C. cajan with osteoblastogenic promoting activity. This study investigated the potential of CLA to prevent postmenopausal obesity and fatty liver. Underlying mechanisms were also investigated. Ovariectomized C57BL/6 mice fed a regular diet were used as mimics of postmenopausal women and given 10, 20, or 40 mg/kg/d of CLA, 0.1 mg/kg/d of estradiol valerate (EV, positive control), or vehicle (OVX) orally for 16 weeks. Mice of the same age subjected to a sham operation were used as control (Sham). Body weights were recorded every 2 weeks for 16 weeks. Body compositions were analyzed via micro-CT. Serum levels of lipids, adipocytokines and aminotransferases were measured using the relevant kits. mRNA levels of genes of interest were detected by RT-qPCR. Proteomic study of perigonadal white adipose tissue (pWAT) was performed using tandem-mass-tags-based proteomic technology combined with Parallel-Reaction-Monitoring (PRM) validation. CLA showed potential equivalent to that of EV to prevent ovariectomy-induced overweight, obesity, dyslipidemia, liver steatosis and liver dysfunction, but did not prevent uterine atrophy. In the liver, CLA significantly inhibited ovariectomy-induced upregulation in expression of lipogenic genes SREBP-1c and ChREBP, and stimulated the mRNA expression of apolipoprotein B gene ApoB. In pWAT, CLA reversed, or partially reversed ovariectomy-induced downregulation in the expression of a number of metabolism- and mitochondrial-function-related proteins, including Ndufa3, Pcx, Pdhb, Acly, Acaca, Aldh2, Aacs and Echs1. In addition, ovariectomy-inhibited mRNA expression of Pdhb, Aacs, Acsm5, Echs1, and Aldh2 genes in pWAT was also reversed. CLA was demonstrated to be a potential non-estrogen-like drug candidate for prevention of postmenopausal obesity and fatty liver. The underlying mechanism might involve the inhibition of lipogenesis and promotion of triglycerides output in the liver, and the promotion of metabolism and mitochondrial functions of visceral white adipose tissue. [Display omitted]